Live
Endpoints NewsBristol Myers’ pivotal year; Should AI be swinging bigger?; and moreEli LillyWhy Eli Lilly (LLY) Is Up 9.0% After Q1 Beat And Foundayo GLP‑1 Launch - And What's Next - simplywall.stWuXi BiologicsWuXi Biologics Advances Global Sustainability Strategy With 2025 ESG Report - BioPharma APACNovo NordiskFDA Proposal Could Support Novo Nordisk GLP‑1 Exclusivity And Valuation - simplywall.stAmgenBiopharma bites: Novo rebrands Rybelsus as the Ozempic pill, and Amgen trims its pipeline - FirstWord PharmaSamsung BiologicsUnionized workers of Samsung Biologics continue strike for 2nd day - lokmattimes.comSamsung BiologicsSamsung Biologics union continues strike regarding wages, other issues - Korea JoongAng DailySamsung BiologicsUnionized workers of Samsung Biologics continue strike for 2nd day - The Korea HeraldBoston ScientificAssessing Boston Scientific’s Valuation As Lower Guidance Weighs On Sentiment After Strong Q1 Results - simplywall.stLab-DirectCardiovascular Pacing and ICD Leads Price in Northern America - Market Insights - IndexBoxMerck KGaAMerck KGaA Backs Hybrid Cancer Drugs And Greener Lab Consumables - simplywall.stBioPharma DiveArvinas’ ‘Protac’ breast cancer drug cleared by FDA
Endpoints News Mar 17, 2026

Drugmakers consider licensing deal tweaks to soften MFN impact

Drugmakers consider licensing deal tweaks to soften MFN impact

Original
Body unavailable. Use the original source.